P. Wen

Publications1,019
h-index109
Citations52,629
Highly Influential Citations1,596
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • T. Cloughesy
  • 802 Publications • 45,982 Citations
  • D. Reardon
  • 703 Publications • 37,826 Citations
  • M. Weller
  • 1,463 Publications • 94,680 Citations
  • W. Wick
  • 825 Publications • 53,223 Citations
  • Publications
  • Influence
Malignant gliomas in adults.
TLDR
Patients with malignant gliomas have a family history of glioma and some of these familial cases are associated with rare genetic syndromes, such as neurofibromatosis types 1 and 2 and Li−Fraumeni syndrome.
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
TLDR
The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies.
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
TLDR
Bvacizumab, alone or in combination with irinotecan, was well tolerated and active in recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial.
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma
TLDR
There is definite hope that by 2020, new cocktails of drugs will be available to target the key molecular pathways involved in gliomas and reduce their mortality and morbidity, a positive development for patients, their families, and medical professionals alike.
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
TLDR
Bortezomib-associated peripheral neuropathy seemed reversible in the majority of patients after dose reduction or discontinuation, and the overall occurrence was independent of baseline neuropathy or type of prior therapy.
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
TLDR
Abemaciclib represents the first selective inhibitor of CDK4 and CDK6 with a safety profile allowing continuous dosing to achieve sustained target inhibition, and this first-in-human experience demonstrates single-agent activity for patients with advanced breast cancer, NSCLC, and other solid tumors.
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
TLDR
It is suggested that the neoadjuvant administration of PD-1 blockade enhances both the local and systemic antitumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor.
Management of brain metastases.
TLDR
Advances have been made in the diagnosis and management of brain metastases, but further studies are needed to define the optimal role of conventional treatments and to develop more effective novel therapies.
Bevacizumab for recurrent malignant gliomas
TLDR
Combination therapy with bevacizumab and chemotherapy is well-tolerated and active against recurrent malignant gliomas and may alter the recurrence pattern of malignantgliomas by suppressing enhancing tumor recurrence more effectively than it suppresses nonenhancing, infiltrative tumor growth.
...
1
2
3
4
5
...